Neumora Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(53,458) | $(67,992) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 7,405 | 9,324 |
| Non-cash operating lease expense | 59 | 877 |
| Depreciation and amortization | 8 | 157 |
| Net accretion of investments in marketable securities | — | (1,289) |
| Gain on disposal of property and equipment | (71) | — |
| Amortization of debt issuance costs and accretion of final payment fee | 418 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,644 | 966 |
| Accounts payable | 1,678 | (2,255) |
| Accrued liabilities | (4,020) | 1,679 |
| Operating lease liabilities | (67) | (915) |
| Net cash used in operating activities | (46,404) | (59,448) |
| Investing activities: | ||
| Purchases of marketable securities | — | (44,385) |
| Proceeds from maturities of marketable securities | — | 88,545 |
| Proceeds from sale of equipment | 71 | — |
| Net cash provided by investing activities | 71 | 44,160 |
| Financing activities: | ||
| Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs | 10,875 | — |
| Net cash provided by financing activities | 10,875 | — |
| Net change in cash and cash equivalents and restricted cash | (35,458) | (15,288) |
| Cash and cash equivalents and restricted cash at beginning of year | 182,530 | 143,361 |
| Cash and cash equivalents and restricted cash at end of period | $147,072 | $128,073 |
| Components of cash and restricted cash: | ||
| Cash and cash equivalents | $147,072 | $126,860 |
| Restricted cash | — | 1,213 |
| Total cash and cash equivalents and restricted cash | $147,072 | $128,073 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,458 | $— |
| Cash paid for income taxes | $30 | $— |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Principal amount of debt extinguished upon conversion to common stock | $2,050 | $— |
| Debt issuance costs reclassified to equity in connection with conversion | $63 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.